IQVIA Raises Full-Year EPS Guidance to $12.80-$13.00 After Q2 Beat
IQV sits 51% above its 52-week low of $154.5.
Summary
IQVIA delivered Q2 revenue of $4.37 billion and adjusted EPS of $3.15, both above the high end of its prior guidance. The company raised its full-year adjusted EPS outlook to $12.80-$13.00, signaling confidence in sustained demand for its clinical research and data analytics services. This follows a strong Q1 and a $2 billion buyback authorization in May, reinforcing a pattern of capital returns alongside operational momentum. The guidance raise lifts the midpoint above consensus and implies accelerating earnings growth in the back half of the year. With the stock near $234, the new range suggests a forward P/E compression that could attract value-oriented buyers. Additionally, IQVIA's stock rose on the second-quarter gains and a ballooning backlog.
At the time of this announcement, IQV was trading at $234.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $35.6B. The 52-week trading range was $154.50 to $247.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.